Roche Holding AG (LON:0QQ6)
303.40
+4.40 (1.47%)
At close: Oct 3, 2025
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.85B CHF in the half year ending June 30, 2025, with 4.03% growth. This brings the company's revenue in the last twelve months to 63.49B, up 4.80% year-over-year. In the year 2024, Roche Holding AG had annual revenue of 62.40B with 3.23% growth.
Revenue (ttm)
63.49B CHF
Revenue Growth
+4.80%
P/S Ratio
3.94
Revenue / Employee
614.90K CHF
Employees
103,249
Market Cap
229.73B GBP
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
Roche Holding AG News
- 2 days ago - FDA Approves Roche's Tecentriq for Lung Cancer Treatment - GuruFocus
- 2 days ago - Roche's Genentech gets FDA nod for lung cancer treatment - Seeking Alpha
- 2 days ago - FDA approves Roche's Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer - GlobeNewsWire
- 2 days ago - Change in the Roche Board of Directors - GlobeNewsWire
- 3 days ago - FDA Approves Genentech's Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer - Business Wire
- 4 days ago - Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR - Nasdaq
- 4 days ago - Trade treaty kicks in, Swiss govt seeks investment pact - The Times of India
- 4 days ago - Roche Initiates Tender Offer for 89bio (ETNB) in $3.5B Acquisition - GuruFocus